Bayer open for drug licensing deals, cutting debt remains priority

Bayer is ready to spend money on more drug licensing agreements like last year’s deal with Loxo Oncology but its priority is to reduce debt after the takeover of Monsanto.

…read more

Source:: Reuters – Business News


Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.